

BCR/ABL preleukemic fusion gene in subpopulations of hematopoietic stem and progenitor cells from human UCB

Lukas Jakl (✉ lukas.jakl@savba.sk)

Ustav experimentalnej onkologie Slovenska Akademia Vied

Milan Škorvaga

Cancer Research Institute, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, 84505, Slovakia

Matúš Durdík

Cancer Research Institute, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, 84505, Slovakia

Pavol Košík

Cancer Research Institute, Biomedical Research Center, University Science Par for Biomedicine, Slovak Academy of Sciences, Bratislava, 84505, Slovakia

Katarína Bérešová

Cancer Research Institute, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, 84505, Slovakia

Jana Jakubíková

Cancer Research Institute, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, 84505, Slovakia

Miroslav Kubeš

Stem Cell Lab, BIOM-R, s.r.o., Bratislava, Slovakia

Marek Holop

Stem Cell Lab, BIOM-R, s.r.o., Bratislava, Slovakia

Eva Marková

The University of Sheffield Medical School

Igor Belyaev

Cancer Research Institute, Biomedical Research Center, University Science Park for Medicine, Slovak Academ of Sciences, Bratislava, 84505, Slovakia

Research article

Keywords: BCR/ABL, preleukemic fusion gene, hematopoietic stem and progenitor cells, umbilical cord blood, children acute leukemia

Posted Date: August 23rd, 2019

DOI: <https://doi.org/10.21203/rs.2.13472/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Neoplasma on January 1st, 2020. See the published version at https://doi.org/10.4149/neo_2019_190925N965.

Abstract

Background BCR/ABL preleukemic fusion gene (PFG) is one of the most frequent fusion genes in acute lymphoblastic leukemia (ALL) and was also detected in hematopoietic cells from umbilical cord blood (UCB) of healthy newborns. Since hematopoietic stem/progenitor cells (HSPC) are considered to be a critical cellular target for origination of leukemia, we have studied the presence of BCR/ABL PFG in expanded subpopulations of HSPC and differentiated cells from UCB of those healthy newborns, who have previously been tested positive for BCR/ABL by screening of their UCB mononuclear cells using RT-qPCR and FISH methods. Methods: We isolated cells from human UCB samples positive for BCR/ABL and negative controls. The isolated cells were sorted into 5 hematopoietic and progenitor cell subpopulations. Sorted cells were expanded and analyzed for the presence of BCR/ABL chromosomal translocation and fusion transcripts by FISH and RT-qPCR, respectively. We analyzed BCR/ABL in sorted and expanded subpopulations of UCB using FISH and RT-qPCR Results: We found that the number of BCR/ABL positive cells was similar in each studied subpopulation and the same as in differentiated lymphocytes. Conclusions: Our data showed that there is no specific subpopulation of hematopoietic and progenitor stem cells with an increased leukemogenic potential due to the presence of higher copies of BCR/ABL.

Background

Pediatric leukemia is a clonal disease arising from the transformation of a single pluripotent hematopoietic stem/progenitor cell (HSPC) [1-3]. The development of acute childhood leukemia is a multistep process driven by the accumulation of genetic abnormalities. First hit representing an initiating event is often a chromosomal translocation resulting in a preleukemic fusion gene (PFG) with a novel/modified activity, usually impairing differentiation of HSPC. PFG may arise predominantly in utero during fetal/embryonic development, producing a persistent, but clinically covert preleukemic clone [1, 3-5]. These clones were detected in umbilical cord blood (UCB) of newborns, usually at frequencies 100-fold higher than incidence of leukemia suggesting relatively late origin and possible elimination of most preleukemic clones further in development [6]. While UCB HSPC have been used for transplantation in treatment of leukemia, the presence of an undiagnosed preleukemic clone in donor's HSPC before transplantation may explain the development of donor cell leukemia (DCL), a rare complication that occurs after allogeneic HSPC transplantation [7] and causes a very high mortality in leukemic recipients [8]. Therefore, the screening of UCB for preleukemic clones based on analysis of PFG may be of high importance for prevention of DCL. In addition, identification of specific HSPC subpopulation(s) in which the PFG is originated can help refine the target cells for therapy leading to a more specific and thus more effective therapy of primarily diagnosed and/or relapsed leukemia. These aspects are highly significant, especially for PFG-associated leukemias with a poor prognosis, including t(9;22)(q34;q11) reciprocal translocation resulting into the Philadelphia (Ph) chromosome and formation of the BCR/ABL fusion gene. Translocation t(9;22)(q34;q11) is the most frequent genetic aberration in adult acute lymphoblastic leukemia (ALL) and is found in 20%-30% of patients overall; it increases with age, approaching 50% in

patients older than 50 years [9, 10]. This PFG is one of the most frequent (3-5%) and prognostically important PFG associated with pediatric acute lymphoid leukemia (ALL).

BCR/ABL is formed by fusion of the break cluster region (BCR) gene with the Abelson tyrosine kinase (ABL1) gene [11]. Depending on the translocation breakpoint in BCR gene, different Bcr-Abl fusion protein isoforms are expressed, with all of them containing exons 2-11 of the ABL1 gene and different sections of BCR component [12]. The most common Bcr-Abl isoforms are p210 and p190 which is 501 amino acid residues shorter (~ 25%) and can be considered as internal deletion mutant of p210. The expression of p210 is the molecular hallmark of chronic myelogenous leukemia (CML) [12]. The Ph-chromosome is also present in 20-30% of adult B-cell ALL with ~ 1/4 and ~ 3/4 expressing p210 and p190, respectively [12].

BCR/ABL fusion gene results into constitutive expression of activated tyrosine kinase (TK). This gene is an important indicator for prognosis in ALL, and is associated with poor overall survival and remission duration. The fusion results into an increased TK activity compared to ABL1 [13]. Since ABL1 regulates the evolution of T-lymphocytes and plays a pivotal role in the process of their cytoskeleton deformation [14], the screening for chimeric ABL1 genes could be considered in ALL-patients, especially in those with T-ALL.

Bcr-Abl is a constitutively active tyrosine kinase and its inhibitors (TKIs) are a paradigm for targeted cancer therapy [15]. P210 is the sole oncogenic driver, sufficient to establish and maintain CML. In contrast, Ph+ B-ALL are frequently associated with additional mutations [16].

Characterizing preleukemic HSPC and understanding the developmental origin and hierarchy in preleukemic HSPC may lead to identification of mechanisms for disease relapse and development of effective therapeutic strategies [17]. During recent years, the focus in treatment of leukemia relapse has shifted towards the development of novel immunotherapeutic strategies [18]. The recent development of novel T-cell-based immunotherapies, initially applied to the treatment of B-cell malignancies, represents an exciting new area of investigation in AML immune therapy [19]. Some of the most promising are drug-conjugated monoclonal antibodies, T-cell engaging antibody constructs, adoptive transfer with chimeric antigen receptor T cells (CAR T cells) and bifunctional antibodies such as bispecific T-cell engagers (BITE) [19, 20]. All these strategies require well characterized membrane markers of pathological cells to be targeted.

Overall, BCR/ABL is one of the most investigated PFG in healthy people, see for review [21]. The incidence of BCR/ABL p190 ranged from 0% up to 80% in studied subjects (newborns, children and adults). In this study, we expanded the rare populations of HSPC from UCB MNC tested positive for BCR/ABL. This knowledge may provide a basis for developing immunotherapeutic strategies to eradicate the rare population of preleukemic stem cells.

Methods

4.1. Sample preparation

The UCB cells originally isolated from healthy donors were obtained from Eurocord Slovakia s.r.o. – Slovak cord blood bank. Cells were thawed as previously described [26, 27] with addition of 100 µg/ml DNase I (Sigma-Aldrich, St.Louis, Missouri, United States) to the RPMI (Gibco, Thermo Fischer Scientific, Waltham, Massachusetts, United States) during thawing in order to prevent formation of clumps. After thawing, centrifugation and counting of cells using 0.4 % Trypan blue solution (Gibco, Thermo Fischer Scientific), cells were incubated in complete media (89 % RPMI, 10 % FBS, 1% ATB) for 30 min in at 37°C at 5% CO₂. Then cells were spun down at 175 g/15 min, cell pellet was resuspended in 5 ml of complete media, and cell suspension was filtrated through 100 µm cell strainer (BD biosciences, San Jose, California, United States) to prevent formation of clogs during cell sorting. The final viability of cells in all experiments reached at least 95%.

4.2. Cell sorting

Sample pellets were resuspended in 400 µl of PBS containing 1% BSA (Sigma-Aldrich) with FC blocking (BD biosciences) in concentration 1:100 and incubated for 10min at RT. For compensation, single-color stained controls and unstained control were prepared by adding 10 µl of cell solution to 30 µl of 1% BSA PBS. The rest of cell solution was used for cell sorting. For immunophenotyping of different cell population following antibody conjugates were used: CD34-APC (Miltenyi Biotec, Bergisch-Gladbach, Germany), CD45-V450, CD38-PeCy7, CD45RA-FITC, CD90-PE and Lineage cocktail (CD56, CD8, CD3 and CD235a-PeCy5) (all BD biosciences). The cells were then incubated for 60 min in fridge. Next, 500µl of 1% BSA PBS was added to each tube and samples were centrifuged for 10 min/800 rpm. Sample was resuspended in 400 µl of 1 % BSA PBS and compensation controls in 200 µl. Finally, 2 µl and 1 µl of 7AAD were added to the sample and Lineage compensation tube, respectively.

Various subpopulations of HSPC were then sorted using BD FACSAria Special research order product (BD biosciences) into separate tubes with 200 µl of complete media according to the expression of different surface antigens:

HSPC: CD45+ CD45RA- CD34+

Progenitors: CD45+ CD45RA- CD34+ CD38+

HSC/MPP: CD45+ CD45RA- CD34+ CD38-

HSC: CD45+ CD45RA- CD34+ CD38- CD90+

MPP: CD45+ CD45RA- CD34+ CD38- CD90-

Purity of cell sorting was at least 95% in each one of the experiments.

4.3. Cell expansion

The sorted cell subpopulations were applied into wells on 24 well plates in volume 1.5 ml of complete expansion media (CEM). CEM for one well contained 1 ml of MEM alpha EAGLE with UltraGlutamine I, deoxyribonucleoside, and ribonucleosides (α MEM) + 0.5 ml IMDM with HEPES w/L-Glutamine (both LONZA) with 10% of FBS (Fetal Bovine Serum, HYCLONE) with 1% of ATB/ATM (Antibiotic/Antimycotic Solution, PAA) containing stem cell factor (25 ng/ml), Flt-3L (25 ng/ml), and trombopoetin (25 ng/ml) (all three R&D Systems). Mesenchymal stem cells (MSC) from umbilical cord in amount of 2×10^4 /well/1ml α MEM as a “feeder” cells were added into the wells 48 h before set the expansion. Optimal concentration of starting cells for every CD34+ subpopulation was 1500 cells/well. The maximum level of expansion achieved was $\sim 1,000x$ multiplication of starting culture. Cells were checked visually in microscope in intervals of every 2 - 4 days and in day 8th of expansion were expanded cells harvested and transferred in fresh CEM into the wells with new MSC feeder. The optimal time for harvesting was defined before the reaching “plateau” phase during 10 - 12 days of expansion, when the multiplication is sufficient and the cells still contain the optimal amount of RNA. The flow cytometry of sorted and expanded CD34+ cells showed that expansion resulted in approximately 10 % of CD34+ cells and 90 % of CD34- cells.

4.4. Fusion gene and transcript detection

The RT-qPCR was performed as described previously [22]. However, the method of cDNA synthesis was dependent on the amount of cells and thus RNA available for the screening. For standard reverse transcription (RT) reaction, 1 μ g of total RNA was used. All “no template controls” (NTC) were negative (0/3) in all RT-qPCR assays. In case of expanded hematopoietic stem/progenitor cell subpopulations yielding often a limited amount of cells and RNA, an amplification of cDNA has been introduced. Using this procedure based on Smart-seq2 [28] a controlled amplification of mRNA-derived cDNA (from 100- up to 140,000-fold) has been obtained.

For FISH analysis, dried slides were washed in KCl (0.55 g/100 ml; pH = 6.8; 10 min; room temperature (RT)) and placed in fixation solution (methanol 75% and 25% acetic acid; 10 min; RT) and dried. Next step was degreasing in xylene (15 min; RT) and dehydration in 96% ethanol (15 min; RT) and repeat washing in KCl and fixation step. The slides were dried in flow box. Next ready to use or diluted probes were applied in volume of 3 μ l(). Slides were covered by cover slips and sealed by Fixogum (Marabu, Bietigheim-Bissingen, Germany) and applied into ThermoBlock on 75°C (CytoCell Aquarius, Cambridge, United Kingdom) for 5 min. The samples were put into humid chamber in incubator on 37°C overnight. The cover slips were removed and the slides were washed in 0.4 x SSC (60 s; 72°C) and immediately in 2 x SSCT (30 s; RT). Next the slides were dehydrated in ethanol row 50%, 70% and 96% for 2 min in every

concentration without drying. After this step the slides were dried in flow in dark. We applied 3 μ l DAPI in concentration 0.125 μ g/ml containing antifade reagent (manufacturer, city, country). The slides were analyzed using fluorescent microscopy in spectrum DAPI, spectrum green, spectrum orange, and spectrum red. We analyzed 200 – 1,000 cells depending on the quality of the nuclei.

4.5. Statistical analysis

Analysis of variance (ANOVA), Fisher exact test and LSD was applied using Statistica software (Dell software, Round Rock, Texas, United States). The results were considered significantly different at $p < 0.05$.

Results

In previous study, UCB mononuclear cells (MNC) from 500 newborns were screened by RT-qPCR for the presence of most prognostically important PFG [6]. Using the same UCB cell bank, we have chosen six BCR/ABL positive and three BCR/ABL negative samples of frozen UCB MNC for sorting, subsequent cell expansion and identification of the subpopulation containing BCR/ABL fusion transcript and correspondent chromosomal translocation by RT-qPCR and FISH methods, respectively. UCB MNC were sorted into five subpopulations: HSPC: CD45+ CD45RA- CD34+; Progenitors: CD45+ CD45RA- CD34+ CD38+; HSC/MPP: CD45+ CD45RA- CD34+ CD38-; HSC: CD45+ CD45RA- CD34+ CD38- CD90+; and MPP: CD45+ CD45RA- CD34+ CD38- CD90-. The range number of expand cells obtained was from 40 000 to 6 million according to number of expansion days and amount of sorted cells entering in expansion. The range of sorted cell amount in subpopulations entered to expansion was from 40 to 10 000 cells. The range of multiplication rate was from 80 to 6250 through all subpopulations. No significant correlation was found among time of expansion, amount cells at the start of expansion, and rate of multiplication.

The results from RT-qPCR and FISH are shown in Table 1 and Table 2, respectively. The RT-qPCR analyses of MNC revealed the BCR/ABL positivity in HSPC of all nine probands, although in previous study MNC were tested as BCR/ABL negative in three of them using the same methodology. This result may be accounted for significant increase in the detection threshold due to cell sorting

The RT-qPCR results show that individual UCB HSPC subpopulations have been tested positive for BCR/ABL, reaching different copy number of the BCR/ABL fusion transcript (from 1 to 76 copies per 100,000 cells). In general, all HSCPC subpopulations were found to be positive for BCR/ABL suggesting that this translocation arise already in most primitive hematopoietic stem cells. The mean level of BCR/ABL positivity, estimated from RT-qPCR data including all probands and cell subpopulations, was ~ 7.05 transcripts per 100,000 cells in our experiments. Our results provide evidence that BCR/ABL PFG is present not only in a single UCB HSPC subpopulation, but more probably it is spread into all HSPC subpopulations. We did not observe any statistically significant differences between subpopulation of HSPC using ANOVA and Fisher LSD ($p > 0.05$).

Using FISH method we identified BCR/ABL chromosomal translocation only in one subpopulation of proband P428, namely in progenitors. The positivity was at the level of 1.5 % in comparison with other subpopulations of this and other probands, in which the BCR/ABL was not found (Table 2). This positivity was unlikely false due to use of a “dual fusion” BCR/ABL probe, specially constructed to eliminate the false positivity that might be caused by a random overlap of two signals (Figure 1). Almost negative data on BCR/ABL chromosomal translocation revealed by FISH is in line with the RT-qPCR data that show that BCR/ABL fusion transcripts are distributed into all analyzed subpopulations reaching in average only 7.05 transcripts per 100,000 cells. This value, even after sorting the MNC cells, is still under the threshold for detection by FISH method.

Discussion

For analyzing cell subpopulations, which may be responsible for leukemogenesis, we sorted HSPC subpopulations from UCB cells using appropriate membrane markers, including CD34, CD38, CD45, CD45RA, and Lin. In these experiments, UCB MNC tested previously as BCR/ABL positive or negative using standard RT-qPCR analysis in triplicates [6] were sorted and expanded. However, all cell subpopulations derived from these UCB MNC were tested BCR/ABL positive by RT-qPCR in our experiments. The sensitivity of our RT-qPCR has been previously analyzed and ratio of positive reactions to all reactions was defined as 0.4 when proportion of BCR/ABL is at least 1 copy/100,000 cells [22]. The positivity in subpopulations of previously tested MNC negative samples could partly be explained by formation of BCR/ABL *trans*-spliced transcripts as a consequence of cell sorting and expansion process *in vitro* [23]. While chromosomal instability has been detected in *ex-vivo* expanded HSC, this instability deals mostly with numerical chromosomal abnormalities with a negligible formation of chromosomal translocations [24]. Thus, it is unlikely that chromosomal translocation resulting in BCR/ABL would be formed during expansion.

Of note, in progenitors from proband P428, which were tested positive by FISH using dual probe with almost 0% false positivity [25], about 8 copies/100 000 cells were found by RT-qPCR analysis in triplicate. The same or even higher BCR/ABL copy number was established by RT-qPCR in some other subpopulations while no positivity was detected therein by FISH. However, relatively low sensitivity of FISH may underlie negative output of FISH analysis in these samples. Another explanation is that RT-qPCR might detect alternative *trans*-splicing product. Ability of FISH probe to detect both BCR/ABL translocations, p190 and p210, while the RT-qPCR primers in our experiments were set for p190 translocation only, may also contribute to the obtained results.

CD34+ HSPC represented about 1% of UCB MNC. Proportion of specific HSPC increased in the sorted subpopulations as follows: CD34+ - by 1,00-fold, CD34+ CD38-, which represented 0.1 % of MNC - by 1000, and CD34+ CD38- CD90+ represented 0.01 – 0.03 % of MNC - by 10,000 – 30,000 333. If we assume the presence of specific subpopulations containing the BCR/ABL positive cells, the probability for identifying the positive cells would be significantly increased upon sorting. Given the BCR/ABL copy number observed by Košík et al. [6] in BCR/ABL positive MNC samples selected for our experiments and

possible preferential formation of BCR/ABL in a specific HSPC subpopulation, this specific sorted subpopulation would contain in average: CD34+ - ~ 1.315 copies per 1,000 cell; CD34+ CD38- - ~ 1.315 copies per 100 cells, and CD34+ CD38- CD90+ - ~ 1.315 copies per 10 – 30 cells. Thus, the sensitivity of FISH might be sufficient to detect PFG positive cells if hypothesis on specific localization of PFG in defined HSPC subpopulation is correct. In contrary to this hypothesis, our RT-qPCR results showed similar proportion of BCR/ABL+ cells in each subpopulation (mean value was ~ 7.05 transcripts per 100,000 cells) indicating a random distribution across all subpopulations. In addition, very similar BCR/ABL incidence was detected in BCR/ABL positive MNC chosen for this study. Thus our data suggest that there is not specific HSPC subpopulation predisposed to formation of BCR/ABL.

Conclusions

To reveal the proportion of BCR/ABL PFG in BCR/ABL positive UCB HSPC subpopulations, we tested the presence of PFG using FISH and RT-qPCR methods in sorted and expanded subpopulations. We concluded that proportion of BCR/ABL positive cells was even and did not depend on immunophenotype of sorted HSPC.

Abbreviations

7-AAD	7-aminoactinomycin D
ABL	Abelson murine leukemia viral oncogene homolog 1 (ABL1)
ASS1	argininosuccinate synthase 1
ATB	antibiotics
BCR	breakpoint cluster region protein
BSA	bovine serum albumin
CD	cluster of differentiation
DAPI	4',6-Diamidino-2-phenylindole
FBS	fetal bovine serum
FISH	fluorescent <i>in situ</i> hybridization
FUBP3	far upstream element binding protein 3
GNAZ	G protein subunit alpha z
HBSS	Hank's Balanced Salt Solution
HSPC	hematopoietic stem and progenitor cells
IGLL1	immunoglobulin lambda like polypeptide 1
IR	ionizing radiation
MNC	mononuclear cells
NTC	no template control
P _{No}	proband number
PBS	phosphate buffered saline
PFG	preleukemic fusion gene
PRDM12	PR/SET domain 12
RAB36	member RAS oncogene family
rpm	rotation per minute
RPMI	Roswell Park Memorial Institute
RT	Room temperature
RT-qPCR	Real time quantitative polymerase chain reaction
SP _{No}	subpopulation number
SSC	saline sodium citrate
UCB	saline sodium citrate

Declarations

Ethics approval and consent to participate: “Ethics approval has been a requirement of the project of Slovak Research and Development Agency (APVV-15-0250)”.

Consent to publish: “All authors have agreed with publishing this manuscript”.

Availability of data and materials: “The manuscript contains all data. No supplementary data are available”.

Competing Interest: “The authors declare no conflict of interest”.

Funding: “This research was funded by the Slovak Research and Development Agency (APVV-15-0250) and by VEGA Grant Agency (2/0087/18) of the Slovak Republic, funders play a role as a financial support only. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results”.

Author Contributions: “conceptualization, I.B.; methodology, L.J., M.Š., K.B., M.D., P.K., J.J., M.K., and M.H.; software, L.J.; validation, I.B., L.J., M.Š.; formal analysis, M.Š. and L.J. and K.B.; investigation, L.J. and M.Š. and K.B.; resources, E.M.; data curation, L.J. and M.Š.; writing—original draft preparation, L.J.; writing—review and editing, I.B.; visualization, L.J.; supervision, I.B.; project administration, I.B. and E.M.; funding acquisition, I.B. All authors have read and approved the manuscript”.

Acknowledgments: none

References

1. Greaves, M. F.; Wiemels, J., Origins of chromosome translocations in childhood leukaemia. *Nature reviews. Cancer* **2003**, 3, (9), 639-49.
2. Ford, A. M.; Palmi, C.; Bueno, C.; Hong, D.; Cardus, P.; Knight, D.; Cazzaniga, G.; Enver, T.; Greaves, M., The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. *The Journal of clinical investigation* **2009**, 119, (4), 826-36.
3. Bueno, C.; Montes, R.; Catalina, P.; Rodriguez, R.; Menendez, P., Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. *Leukemia* **2011**, 25, (3), 400-10.
4. Greaves, M. F.; Maia, A. T.; Wiemels, J. L.; Ford, A. M., Leukemia in twins: lessons in natural history. *Blood* **2003**, 102, (7), 2321-33.
5. Mori, H.; Colman, S. M.; Xiao, Z.; Ford, A. M.; Healy, L. E.; Donaldson, C.; Hows, J. M.; Navarrete, C.; Greaves, M., Chromosome translocations and covert leukemic clones are generated during normal fetal development. *Proc Natl Acad Sci U S A* **2002**, 99, (12), 8242-7.

6. Kosik, P.; Skorvaga, M.; Durdik, M.; Jakl, L.; Nikitina, E.; Markova, E.; Kozics, K.; Horvathova, E.; Belyaev, I., Low numbers of pre-leukemic fusion genes are frequently present in umbilical cord blood without affecting DNA damage response. *Oncotarget* **2017**, *8*, (22), 35824-35834.
7. Wiseman, D. H., Donor cell leukemia: a review. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* **2011**, *17*, (6), 771-89.
8. Shiozaki, H.; Yoshinaga, K.; Kondo, T.; Imai, Y.; Shiseki, M.; Mori, N.; Teramura, M.; Motoji, T., Donor cell-derived leukemia after cord blood transplantation and a review of the literature: Differences between cord blood and BM as the transplant source. *Bone Marrow Transplantation* **2014**, *49*, (1), 102-109.
9. Radich, J. P., Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia. *Hematology/Oncology Clinics of North America* **2001**, *15*, (1), 21-36.
10. Gökbuget, N.; Hoelzer, D., Treatment of Adult Acute Lymphoblastic Leukemia. *ASH Education Program Book* **2006**, 2006, (1), 133-141.
11. Wong, S.; Witte, O. N., The BCR/ABL story: bench to bedside and back. *Annual review of immunology* **2004**, *22*, 247-306.
12. Deininger, M. W.; Goldman, J. M.; Melo, J. V., The molecular biology of chronic myeloid leukemia. *Blood* **2000**, *96*, (10), 3343-56.
13. Morel, F.; Herry, A.; Le Bris, M. J.; Morice, P.; Bouquard, P.; Abgrall, J. F.; Berthou, C.; De Braekeleer, M., Contribution of fluorescence in situ hybridization analyses to the characterization of masked and complex Philadelphia chromosome translocations in chronic myelocytic leukemia. *Cancer Genetics and Cytogenetics* **2003**, *147*, (2), 115-120.
14. Colicelli, J., ABL tyrosine kinases: evolution of function, regulation, and specificity. *Sci Signal* **2010**, *3*, (139).
15. O'Hare, T.; Zabriskie, M. S.; Eiring, A. M.; Deininger, M. W., Pushing the limits of targeted therapy in chronic myeloid leukaemia. *Nature reviews. Cancer* **2012**, *12*, (8), 513-26.
16. Mullighan, C. G.; Downing, J. R., Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. *Leukemia* **2009**, *23*, 1209.
17. Aoki, Y.; Watanabe, T.; Saito, Y.; Kuroki, Y.; Hijikata, A.; Takagi, M.; Tomizawa, D.; Eguchi, M.; Eguchi-Ishimae, M.; Kaneko, A.; Ono, R.; Sato, K.; Suzuki, N.; Fujiki, S.; Koh, K.; Ishii, E.; Shultz, L. D.; Ohara, O.; Mizutani, S.; Ishikawa, F., Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. *Blood* **2015**, *125*, (6), 967-80.
18. Rambaldi, A.; Biagi, E.; Bonini, C.; Biondi, A.; Introna, M., Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. *Leukemia* **2015**, *29*, (1), 1-10.
19. Grosso, D. A.; Hess, R. C.; Weiss, M. A., Immunotherapy in Acute Myeloid Leukemia. *Cancer-Am Cancer Soc* **2015**, *121*, (16), 2689-2704.
20. Lichtenegger, F. S.; Krupka, C.; Kohnke, T.; Subklewe, M., Immunotherapy for Acute Myeloid Leukemia. *Semin Hematol* **2015**, *52*, (3), 207-214.

21. Kosik, P.; Skorvaga, M.; Belyaev, I., Incidence of preleukemic fusion genes in healthy subjects. *Neoplasma* **2016**, 63, (5), 659-72.
22. Skorvaga, M.; Nikitina, E.; Kubes, M.; Kosik, P.; Gajdosechova, B.; Leitnerova, M.; Copakova, L.; Belyaev, I., Incidence of common preleukemic gene fusions in umbilical cord blood in Slovak population. *PLoS one* **2014**, 9, (3), e91116.
23. Kowarz, E.; Merkens, J.; Karas, M.; Dingermann, T.; Marschalek, R., Premature transcript termination, trans-splicing and DNA repair: a vicious path to cancer. *American journal of blood research* **2011**, 1, (1), 1-12.
24. Ge, J.; Cai, H.; Tan, W. S., Chromosomal stability during ex vivo expansion of UCB CD34(+) cells. *Cell Proliferat* **2011**, 44, (6), 550-557.
25. Ventura, R. A.; Martin-Subero, J. I.; Jones, M.; McParland, J.; Gesk, S.; Mason, D. Y.; Siebert, R., FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. *The Journal of molecular diagnostics : JMD* **2006**, 8, (2), 141-51.
26. Vasilyev, S. A.; Kubes, M.; Markova, E.; Belyaev, I., DNA damage response in CD133 + stem/progenitor cells from umbilical cord blood: low level of endogenous foci and high recruitment of 53BP1. *International journal of radiation biology* **2013**, 89, (4), 301-9.
27. Durdik, M.; Kosik, P.; Gursky, J.; Vokalova, L.; Markova, E.; Belyaev, I., Imaging flow cytometry as a sensitive tool to detect low-dose-induced DNA damage by analyzing 53BP1 and gammaH2AX foci in human lymphocytes. *Cytometry. Part A : the journal of the International Society for Analytical Cytology* **2015**, 87, (12), 1070-8.
28. Picelli, S.; Faridani, O. R.; Björklund, Å. K.; Winberg, G.; Sagasser, S.; Sandberg, R., Full-length RNA-seq from single cells using Smart-seq2. *Nature Protocols* **2014**, 9, 171.

Tables

Table 1. Real-time quantitative PCR analysis revealed BCR/ABL positivity in expanded UCB HSCPC subpopulations from all tested probands

proband/subpopulation	HSPC	Progenitors	HSC/MPP	HSC	MPP
P327	0; 3; 5	10; 10; 0	0; 0; 3	0; 8; 13	2; 0; 3
P138	2; 4; 1	2; 1; 1	5; 2; 3	N/A	N/A
P292	16; 11; 18	31; 30; 41	8; 0; 63	N/A	N/A
P546	N/A	0; 0	0; 0; 3	5; 0; 0	5; 0; 0
P225	2; 0; 0	0; 0; 0	0; 0;	0; 0; 0	2; 0
P257	2; 0; 9	4; 11; 0	11; 15; 13	23; 11; 7	26; 7; 0
P428	9; 7; 3	4; 17; 5	3; 9; 7	1; 9; 13	13; 5
P431	N/A	14; 5; 7	4; 6; 4	A	40; 61; 28
P391	3; 5; 1	12; 6; 6	0; 0; 0	0; 0; 4	0; 5

Legend: copy number of BCR/ABL (p190) per 100,000 cells in triplicates/duplicates are shown; probands originally tested as MNC-negative are designated in bold; subpopulations that failed to expand are shown as N/A; neat, 1:10 and 1:20 dilutions of amplified cDNA used as template in qPCR, all three samples being positive, are designated by A.

Table 2. FISH analysis revealed BCR/ABL fusion gene in UCB progenitors of one out from nine probands. Number of positive/analyzed cells is shown. The samples that failed to expand are shown as N/A.

proband/subpopulation	HSPC	Progenitors	HSC/MPP	HSC	MPP
P327	N/A	0/200	0/1000	0/1000	0/1000
P138	0/1000	0/1000	0/1000	N/A	N/A
P292	0/1000	0/1000	0/1000	N/A	N/A
P546	N/A	0/200	0/1000	0/1000	0/200
P225	0/200	N/A	N/A	0/500	N/A
P257	0/1000	0/1000	0/1000	0/1000	N/A
P428	0/200	3/200	0/500	0/1000	0/1000
P431	0/1000	0/1000	0/1000	0/1000	0/1000
P391	0/1000	0/1000	0/1000	0/1000	0/1000

Figures




Figure 1

Representative image of BCR/ABL positive cell (upper row) and negative cells (bottom row). Nuclei of the cells are stained by DAPI in blue. Green and red spots represent the BCR and ABL region, correspondently. BCR/ABL negative cell displays two red spots and two green spots while BCR/ABL positive cell contains two green spots and three red spots (one intact, one co-localized with green spot showing BCR/ABL fusion, and one as a reciprocal product).